A patient drinks a 75-gram oral glucose solution during a tolerance test and her insulin climbs sharply. A separate protocol gives her an intravenous glucose infusion titrated to produce the exact same blood glucose curve, minute by minute. Her insulin response to the IV glucose is markedly smaller than the oral response, even though the glucose exposure was matched. That gap is not a lab artifact. It is the incretin effect, and it is the single physiological fact that explains why GLP-1 receptor agonists work at all, why GIP was written off as a minor player for 30 years, and why the newest generation of injectable therapies targets both hormones instead of one.
What the Incretin Effect Actually Is
The incretin effect is defined as the proportion of postprandial insulin secretion attributable to gut-derived hormones rather than to blood glucose concentration alone. It was first demonstrated using isoglycemic clamp studies in the 1960s, when researchers showed that oral glucose produced a substantially larger insulin response than intravenous glucose matched to an identical glycemic curve. If glucose alone drove insulin secretion, the two routes should produce identical insulin output. They do not.
In adults with normal glucose tolerance, this gut-to-pancreas signal accounts for roughly 50% to 70% of the insulin secreted after a meal, with the remainder attributable to the direct glycemic stimulus on the beta cell (Nauck et al., Diabetologia 1986, PMID 3514343). That is a majority share of a core metabolic response coming from the intestine, not the bloodstream glucose level itself, which is part of why gut hormone physiology became a pharmaceutical target rather than a biochemistry footnote.
The clinical significance follows directly from the definition. Any drug that mimics or restores incretin signaling has a mechanistic reason to improve glycemic control independent of whatever a patient eats, because it is amplifying an endogenous amplification system rather than introducing a wholly novel pathway. That is a meaningfully different pharmacological strategy than, for example, sulfonylureas, which force insulin release regardless of glucose level.
GLP-1: Source, Speed, and Downstream Signaling
Glucagon-like peptide-1 is synthesized by L-cells concentrated in the distal ileum and colon, though some L-cells are present more proximally as well. Nutrient contact in the gut lumen — particularly fat and carbohydrate — triggers GLP-1 release within minutes of eating, well before nutrients could plausibly have reached the distal gut, a paradox explained partly by neural and proximal L-cell signaling rather than direct nutrient transit alone.
Native GLP-1 has a circulating half-life of roughly 1 to 2 minutes before dipeptidyl peptidase-4 (DPP-4) cleaves it into an inactive metabolite, which is the pharmacological reason DPP-4 inhibitors exist and the reason therapeutic GLP-1 analogs require structural modification (fatty acid acylation in semaglutide, for example) to resist that degradation and extend half-life to roughly a week.
Functionally, GLP-1 acts on pancreatic beta cells to stimulate glucose-dependent insulin secretion, on alpha cells to suppress glucagon, on the stomach to slow gastric emptying, and on hypothalamic and brainstem GLP-1 receptors to reduce appetite. This multi-organ signature is why GLP-1 receptor agonists affect glycemia and body weight simultaneously rather than through two unrelated mechanisms. The appetite-suppressing arm of this pathway is also the basis for pairing GLP-1 agonism with amylin-pathway drugs, a combination strategy detailed in the cagrilintide and GLP-1 pairing analysis.
GIP: The Incretin That Was Overlooked
Glucose-dependent insulinotropic polypeptide, originally named gastric inhibitory peptide before its insulin-stimulating role was fully characterized, is secreted by K-cells concentrated in the duodenum and proximal jejunum. In absolute terms, GIP is released in larger quantities after a meal than GLP-1, and in healthy individuals it is actually the dominant incretin by volume of insulinotropic signal.
GIP's circulating half-life is longer than GLP-1's, on the order of 5 to 7 minutes before DPP-4 degradation, though still short enough that native GIP is not a viable standalone drug without structural modification. For roughly three decades after GIP's insulinotropic role was established, pharmaceutical interest focused almost entirely on GLP-1, because early data suggested GIP's effect was essentially absent in type 2 diabetes, making it look like a dead end for a diabetes drug target.
That assumption turned out to be only half right. The defect in type 2 diabetes is not that K-cells stop releasing GIP — circulating GIP levels are often normal or even elevated. The defect is that beta cells lose responsiveness to GIP signaling, a distinction that matters because it reframed GIP from "irrelevant hormone" to "receptor-level problem that might be pharmacologically correctable," which is the premise underlying every dual agonist developed since (Baggio & Drucker, Gastroenterology 2007, PMID 17498508).
Receptor Pharmacology: Why Binding Affinity Isn't the Whole Story
GLP-1 and GIP act through distinct class B G-protein-coupled receptors — GLP-1R and GIPR — expressed on pancreatic beta cells, with GLP-1R also expressed in the hypothalamus, brainstem, heart, and kidney. Receptor activation triggers a cAMP-dependent signaling cascade that potentiates glucose-stimulated insulin secretion rather than triggering insulin release independent of glucose, which is the molecular basis for the "glucose-dependent" qualifier in both hormone names and the reason hypoglycemia risk from these pathways alone is low.
Potency differences between drugs in this class are not purely a matter of how tightly a molecule binds its receptor. Tirzepatide, for instance, was engineered as a dual GIP/GLP-1 receptor agonist with a deliberately biased signaling profile — strong GIPR activation paired with GLP-1R agonism that is weighted toward cAMP production with reduced beta-arrestin recruitment relative to native GLP-1, a bias associated with reduced receptor internalization and sustained signaling (Coskun et al., Molecular Metabolism 2018). That is a meaningfully different engineering approach than simply maximizing binding affinity at both receptors.
This distinction matters clinically because it means two drugs can have comparable raw binding numbers and still produce different efficacy and tolerability profiles depending on which downstream signaling pathway each agonist preferentially engages. Oral non-peptide candidates introduce a further variable, since small-molecule GLP-1 receptor agonists such as orforglipron bind the same receptor through a different chemical scaffold entirely, a contrast explored in the orforglipron mechanism comparison.
Why the Incretin Effect Collapses in Type 2 Diabetes
The original demonstration that the incretin effect is reduced in type 2 diabetes used isoglycemic clamp methodology to show that, despite matched glucose exposure, patients with type 2 diabetes derived a smaller insulin boost from oral glucose relative to IV glucose than healthy controls (Nauck et al., Diabetologia 1986, PMID 3514343). Later work narrowed the mechanism further: GLP-1's insulinotropic potency is relatively preserved in type 2 diabetes even though absolute secretion may be mildly reduced, while GIP's insulinotropic potency is severely blunted at the beta-cell receptor level.
This asymmetry explains a pattern that initially puzzled researchers — why GLP-1-based drugs produced meaningful glycemic benefit in type 2 diabetes while native GIP infusion studies in the same population showed minimal insulin response. The receptor defect, not a secretion defect, was the bottleneck.
It also explains why clinicians should not assume all incretin pathways degrade uniformly with disease duration or glycemic control. The GIP defect appears early and is substantial, while the GLP-1 defect is comparatively modest, which is a specific, falsifiable claim worth distinguishing from the generic statement that "incretin hormones stop working" in diabetes — they do not stop working equally.
Dual and Triple Agonists: Engineering Around the GIP Problem
Once researchers understood that the GIP defect in type 2 diabetes was a receptor-responsiveness problem rather than a hormone-shortage problem, the logical next step was testing whether pharmacologic GIP receptor agonism, at doses well above physiologic range, could overcome that blunted responsiveness. Tirzepatide was the first unimolecular dual GIP/GLP-1 receptor agonist to reach approval, and subsequent development has extended the same logic to triple agonists incorporating glucagon receptor activity.
Mazdutide and survodutide both pursue a related but distinct strategy, combining GLP-1 receptor agonism with glucagon receptor agonism rather than GIP receptor agonism, aiming to add hepatic fat oxidation and energy expenditure effects on top of appetite suppression. Phase 3 data on the mazdutide program and Phase 2 liver-fat outcomes from survodutide are summarized in the mazdutide Phase 3 trial review and the survodutide Phase 2 data analysis, respectively.
The broader pattern across this drug class is that each added receptor target is a hypothesis about which blunted or underused physiological pathway is worth re-engaging pharmacologically, not simply a strategy of stacking more hormone activity for its own sake. Comparative effectiveness between these dual-mechanism approaches and amylin-based combinations is still being generated in head-to-head trials, an area covered in the CagriSema versus tirzepatide REDEFINE trial comparison.
Appetite, Not Just Glucose: The Weight Loss Connection
The incretin effect was characterized originally as a glucose-handling phenomenon, but GLP-1 receptors in the hypothalamic arcuate nucleus and brainstem area postrema give the same pathway a second, independent role in appetite regulation. Slowed gastric emptying from GLP-1 receptor activation extends gastric distension and satiety signaling, while central GLP-1R activation appears to directly reduce food intake in animal models independent of gastric effects, a distinction that matters for understanding why GLP-1 drugs reduce caloric intake rather than simply delaying hunger.
GIP's role in appetite is less settled. Native GIP has historically been studied mainly for its effects on adipose tissue lipid storage, and some preclinical models associate it with fat accumulation rather than fat loss. Yet pharmacologic co-agonism of GIPR alongside GLP-1R produces greater weight loss in clinical trials than GLP-1R agonism alone, a finding that has prompted competing hypotheses about central versus peripheral GIP action, receptor desensitization dynamics, and dose-dependent effects that differ from what native GIP physiology would predict [CITATION NEEDED: mechanistic trial isolating the independent contribution of GIP receptor agonism to weight loss versus GLP-1 receptor agonism alone].
Weight loss from incretin-based therapy is not uniformly lean mass-sparing, a separate consideration from the appetite mechanism itself. Body composition substudies using DEXA scanning have quantified the proportion of weight loss attributable to lean versus fat mass on these agents, findings summarized in the DEXA substudy review on muscle loss during GLP-1 therapy.
What Remains Unresolved in Incretin Research
Several questions in this field do not yet have consensus answers. The precise central nervous system distribution and functional role of GIP receptors relative to GLP-1 receptors is still being mapped, and the degree to which GIP's weight effect in combination therapy is centrally versus peripherally mediated remains an open methodological problem rather than a settled finding.
The durability of incretin-effect restoration with chronic dual-agonist therapy — whether beta-cell GIP responsiveness genuinely recovers over months of treatment, as opposed to the drug simply bypassing the defect pharmacologically at supraphysiologic exposure — has not been definitively established in humans. This distinction matters for predicting what happens to glycemic control after a dual agonist is discontinued.
Population-level variability is another open area. Not every patient with type 2 diabetes has an identical degree of GIP receptor blunting, and there is currently no validated clinical biomarker that predicts, before starting therapy, which patients will derive the largest incremental benefit from GIP co-agonism versus GLP-1 monotherapy. Until that kind of predictive tool exists, treatment selection remains a matter of clinical trial and guideline-based judgment rather than individualized receptor-level targeting.
For a clinician or researcher evaluating this mechanism, the actionable next step is to review the isoglycemic clamp literature directly rather than relying on secondary summaries, since the magnitude of the incretin effect and its degree of impairment vary meaningfully across study populations, glucose tolerance status, and methodology.
This article summarizes research and does not constitute medical advice. Consult a licensed clinician for diagnosis, treatment, or any decisions about medications or supplements.